KATP channel therapeutics at the bedside

A. Jahangir, Andre Terzic

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

The family of potassium channel openers regroups drugs that share the property of activating adenosine triphosphate-sensitive potassium (K ATP) channels, metabolic sensors responsible for adjusting membrane potential-dependent functions to match cellular energetic demands. K ATP channels, widely represented in metabolically-active tissue, are heteromultimers composed of an inwardly rectifying potassium channel pore and a regulatory sulfonylurea receptor subunit, the site of action of potassium channel opening drugs that promote channel activity by antagonizing ATP-induced pore inhibition. The activity of KATP channels is critical in the cardiovascular adaptive response to stress, maintenance of neuronal electrical stability, and hormonal homeostasis. Thereby, KATP channel openers have a unique therapeutic spectrum, ranging from applications in myopreservation and vasodilatation in patients with heart or vascular disease to potential clinical use as bronchodilators, bladder relaxants, islet cell protector, antiepileptics and promoters of hair growth. While the current experience in practice with potassium channel openers remains limited, multitude of ongoing investigations aims at defining the benefit of this emerging family of therapeutics in diverse disease conditions associated with metabolic distress.

Original languageEnglish (US)
Pages (from-to)99-112
Number of pages14
JournalJournal of Molecular and Cellular Cardiology
Volume39
Issue number1
DOIs
StatePublished - Jul 2005

Fingerprint

KATP Channels
Potassium Channels
Adenosine Triphosphate
Sulfonylurea Receptors
Inwardly Rectifying Potassium Channel
Bronchodilator Agents
Islets of Langerhans
Vascular Diseases
Vasodilation
Pharmaceutical Preparations
Membrane Potentials
Anticonvulsants
Hair
Heart Diseases
Urinary Bladder
Homeostasis
Therapeutics
Maintenance
Growth

Keywords

  • Alopecia
  • Angina pectoris
  • Asthma
  • ATP-sensitive K channels
  • Hypertension
  • Impotence
  • Ischemic heart disease
  • Kir6.1
  • Kir6.2
  • Neuroprotection
  • Peripheral vascular disease
  • SUR1
  • SUR2

ASJC Scopus subject areas

  • Molecular Biology
  • Cardiology and Cardiovascular Medicine

Cite this

KATP channel therapeutics at the bedside. / Jahangir, A.; Terzic, Andre.

In: Journal of Molecular and Cellular Cardiology, Vol. 39, No. 1, 07.2005, p. 99-112.

Research output: Contribution to journalArticle

@article{386a22ad541a41209864bcf933251221,
title = "KATP channel therapeutics at the bedside",
abstract = "The family of potassium channel openers regroups drugs that share the property of activating adenosine triphosphate-sensitive potassium (K ATP) channels, metabolic sensors responsible for adjusting membrane potential-dependent functions to match cellular energetic demands. K ATP channels, widely represented in metabolically-active tissue, are heteromultimers composed of an inwardly rectifying potassium channel pore and a regulatory sulfonylurea receptor subunit, the site of action of potassium channel opening drugs that promote channel activity by antagonizing ATP-induced pore inhibition. The activity of KATP channels is critical in the cardiovascular adaptive response to stress, maintenance of neuronal electrical stability, and hormonal homeostasis. Thereby, KATP channel openers have a unique therapeutic spectrum, ranging from applications in myopreservation and vasodilatation in patients with heart or vascular disease to potential clinical use as bronchodilators, bladder relaxants, islet cell protector, antiepileptics and promoters of hair growth. While the current experience in practice with potassium channel openers remains limited, multitude of ongoing investigations aims at defining the benefit of this emerging family of therapeutics in diverse disease conditions associated with metabolic distress.",
keywords = "Alopecia, Angina pectoris, Asthma, ATP-sensitive K channels, Hypertension, Impotence, Ischemic heart disease, Kir6.1, Kir6.2, Neuroprotection, Peripheral vascular disease, SUR1, SUR2",
author = "A. Jahangir and Andre Terzic",
year = "2005",
month = "7",
doi = "10.1016/j.yjmcc.2005.04.006",
language = "English (US)",
volume = "39",
pages = "99--112",
journal = "Journal of Molecular and Cellular Cardiology",
issn = "0022-2828",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - KATP channel therapeutics at the bedside

AU - Jahangir, A.

AU - Terzic, Andre

PY - 2005/7

Y1 - 2005/7

N2 - The family of potassium channel openers regroups drugs that share the property of activating adenosine triphosphate-sensitive potassium (K ATP) channels, metabolic sensors responsible for adjusting membrane potential-dependent functions to match cellular energetic demands. K ATP channels, widely represented in metabolically-active tissue, are heteromultimers composed of an inwardly rectifying potassium channel pore and a regulatory sulfonylurea receptor subunit, the site of action of potassium channel opening drugs that promote channel activity by antagonizing ATP-induced pore inhibition. The activity of KATP channels is critical in the cardiovascular adaptive response to stress, maintenance of neuronal electrical stability, and hormonal homeostasis. Thereby, KATP channel openers have a unique therapeutic spectrum, ranging from applications in myopreservation and vasodilatation in patients with heart or vascular disease to potential clinical use as bronchodilators, bladder relaxants, islet cell protector, antiepileptics and promoters of hair growth. While the current experience in practice with potassium channel openers remains limited, multitude of ongoing investigations aims at defining the benefit of this emerging family of therapeutics in diverse disease conditions associated with metabolic distress.

AB - The family of potassium channel openers regroups drugs that share the property of activating adenosine triphosphate-sensitive potassium (K ATP) channels, metabolic sensors responsible for adjusting membrane potential-dependent functions to match cellular energetic demands. K ATP channels, widely represented in metabolically-active tissue, are heteromultimers composed of an inwardly rectifying potassium channel pore and a regulatory sulfonylurea receptor subunit, the site of action of potassium channel opening drugs that promote channel activity by antagonizing ATP-induced pore inhibition. The activity of KATP channels is critical in the cardiovascular adaptive response to stress, maintenance of neuronal electrical stability, and hormonal homeostasis. Thereby, KATP channel openers have a unique therapeutic spectrum, ranging from applications in myopreservation and vasodilatation in patients with heart or vascular disease to potential clinical use as bronchodilators, bladder relaxants, islet cell protector, antiepileptics and promoters of hair growth. While the current experience in practice with potassium channel openers remains limited, multitude of ongoing investigations aims at defining the benefit of this emerging family of therapeutics in diverse disease conditions associated with metabolic distress.

KW - Alopecia

KW - Angina pectoris

KW - Asthma

KW - ATP-sensitive K channels

KW - Hypertension

KW - Impotence

KW - Ischemic heart disease

KW - Kir6.1

KW - Kir6.2

KW - Neuroprotection

KW - Peripheral vascular disease

KW - SUR1

KW - SUR2

UR - http://www.scopus.com/inward/record.url?scp=20644438226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20644438226&partnerID=8YFLogxK

U2 - 10.1016/j.yjmcc.2005.04.006

DO - 10.1016/j.yjmcc.2005.04.006

M3 - Article

C2 - 15953614

AN - SCOPUS:20644438226

VL - 39

SP - 99

EP - 112

JO - Journal of Molecular and Cellular Cardiology

JF - Journal of Molecular and Cellular Cardiology

SN - 0022-2828

IS - 1

ER -